NXTC Q2 2025 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$27M

Net Income

-$27M

EPS (Diluted)

$-11.29

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$588,000

Balance Sheet

Total Assets

$48M

Total Liabilities

$16M

Stockholders' Equity

$32M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$701,000	+100.0%
Operating Income	-$27M	-$16M	-65.5%
Net Income	-$27M	-$15M	-74.0%